[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogeneic-stem-cell-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogeneic-stem-cell-transplant":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100212886","phase-1-donor-derived-viral-specific-t-cells-vsts-100212886",false,"NCT02048332","Donor-Derived Viral Specific T-cells (VSTs)","Donor-Derived Viral Specific T-cells (VSTs) for Treatment of Viral Infections After Allogeneic Stem Cell Transplant","VSTs","Inclusion Criteria:\n\n* Recipient must be at least 21 days after stem cell infusion\n* Clinical status must allow tapering of steroids to 0.5mg\u002Fkg prednisone or other steroid equivalent\n* Recipient must have achieved engraftment with ANC ≥ 500\n\nExclusion Criteria:\n\n* Active acute GVHD grades II-IV\n* Uncontrolled bacterial or fungal infection\n* Uncontrolled relapse of malignancy requiring treatment with chemotherapy\n* Infusion of ATG or alemtuzumab within 2 weeks of VST infusion","ALL","4 Weeks",{"count":20,"type":21},750,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant. A viral specific T cell is a T lymphocyte (a type of white blood cell) that kills cells that are infected (particularly with viruses). Allogeneic means the stem cells come from another person. These VSTs are cells specially designed to fight the virus infections that can happen after a bone marrow transplant.\n\nThe investigators are asking people who have undergone or will undergo an allogeneic stem cell transplant to enroll in this research study, because viral infections are a common problem after allogeneic stem cell transplant and can cause significant complications including death.\n\nStem cell transplant reduces a person's ability to fight infections. There is an increased risk of getting new viral infections or reactivation of viral infections that the patient has had in the past, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV), BK virus (BKV), and JC virus. There are anti-viral medicines available to treat these infections, though not all patients will respond to the standard treatments. Moreover, treatment of viral infections is expensive and time consuming, with families often administering prolonged treatments with intravenous anti-viral medications, or patients requiring prolonged admissions to the hospital. The medicines can also have side effects like damage to the kidneys or reduction in the blood counts, so in this study the investigators are trying to find an easier way to treat these infections.",[28,29,30],"Allogeneic Stem Cell Transplant","Viral Infection","Viral Reactivation",[32,33,34,35,36,37,38,39],"Epstein-Barr Virus (EBV)","Adenovirus (ADV)","t-cells","donor","transplant","children","cytomegalovirus (CMV)","BK virus (BKV)","RECRUITING","2025-12-10",{"date":43,"type":44},"2025-12-16","ACTUAL",{"date":46,"type":44},"2014-02-05",{"date":48,"type":21},"2027-01",{"name":50,"class":51},"Children's Hospital Medical Center, Cincinnati","OTHER",3,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100576364","phase-2-phase-ii-study-of-resistant-potato-starch-plus-deferasirox-to-improve-outcomes-in-patients-undergoing-allogeneic-stem-cell-transplantation-100576364","NCT06784336","Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation","Phase II Multi-center Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients with hematologic disorders undergoing allo-HCT from fully HLA-matched unrelated or related donors after full-intensity conditioning regimen\n* Age ≥18 years\n* Karnofsky performance status \\>70%, see Appendix A\n* Patients must be able to swallow capsules\u002Ftablets\n* Ability to understand and the willingness to sign a written informed consent\n* Availability of a full-HLA matched related or unrelated donor who is medically eligible to donate cells according to the National Marrow Donor Program criteria\n\nExclusion Criteria:\n\n* Patients with active inflammatory bowel disease requiring treatment per treating investigator\n* Patients with a history of gastric bypass surgery\n* Patients with active Clostridium difficile infection at the time of study enrollment. Active infection is defined as a stool sample positive for Clostridium difficile toxin via enzyme immunoassay (EIA) and either symptoms (frequent loose stools) OR imaging findings consistent with toxic megacolon\n* Patients with active iron deficiency anemia requiring treatment\n* Patients with iron overload receiving active treatment with deferasirox\n* Known hypersensitivity to deferasirox or any component of Jadenu or Exjade\n* Patients actively enrolled on treatment or in follow up phase on any other GVHD prevention trial\n* Any physical or psychological condition that, in the opinion of the investigator, would pose an unacceptable risk to the patient or raise concern that the patient would not comply with protocol procedures","18 Years",{"count":62,"type":21},50,[25],"The study will evaluate the safety and early efficacy of administering the combination of a commercially available potato-based resistant starch along with iron chelation therapy to subjects undergoing alloHCT.",[28],"2025-11-21",{"date":68,"type":44},"2025-11-28",{"date":70,"type":44},"2025-10-15",{"date":72,"type":21},"2029-10",{"name":74,"class":51},"University of Michigan Rogel Cancer Center",1]